@FierceMedDev: 1,000 people (and rising) are gearing up to sue Medtronic over its Infuse bone growth implant. More | Follow @FierceMedDev
@MarkHFierce: Uh-oh for Thoratec. Some heart pump safety troubles. Story via WSJ (sub. req.) | Follow @MarkHFierce
@GalenMoore: Upheld: Former Spectranetics CEO's conviction for lying to the feds over device smuggling allegations. Story | Follow @GalenMoore
@EmilyWFierce: GE Healthcare slapped with FDA's most serious recall for some of its infant resuscitation products. More | Follow @EmilyWFierce
> Atossa Genetics' 510(k) application for its ForeCYTE Breast Aspirator test has taken an interesting turn with the FDA requesting additional information about the product's development. Item
> TransEnterix, a maker of flexible surgical instruments and robotics, said its revenue dipped and net losses climbed during its fiscal 2013 fourth quarter. Item
> NuVu Studio in Cambridge, MA, wants students to develop a 3-D prosthetic hand for children. Story
> A North Carolina surgeon has developed a medical implant designed to trigger an orgasm for patients unable to achieve them. Clinical trials will begin later this year in Minneapolis. Story
Biotech News
@FierceBiotech: FDA rejects Eli Lilly's SGLT2 diabetes drug empagliflozin. More | Follow @FierceBiotech
@JohnCFierce: Analysts applaud as Bristol-Myers preps a PhIII study for PD-1 cancer combo. Editor's Corner | Follow @JohnCFierce
@DamianFierce: FDA rejects Lilly and Boehringer's diabetes drug (SGLT2-blocker) over manufacturing issue. Release | Follow @DamianFierce
@EmilyMFierce: This week's issue of FierceBiotech Research is out: Read | Follow @EmilyMFierce
> Biogen Idec buys into Eisai's BACE camp on Alzheimer's as drug race heats up. News
> Xoma drug fails to beat out a placebo in PhII osteoarthritis study. Article
Pharma News
@FiercePharma: With tough Japanese enforcers eyeing its Blopress marketing, Takeda chief admits missteps. Story | Follow @FiercePharma
@TracyStaton: This year's version of FiercePharma's most popular special report: The top 10 pharma companies by 2013 revenue. Report | Follow @TracyStaton
@EricPFierce: WSJ says Pfizer angling for OTC Lipitor. That will get generic drugmakers' notice. More | Follow @EricPFierce
@CarlyHFierce: Roche, by the way, was No. 3 when it comes to 2013 revenue - read more here and see the rest of the top 10. Report | Follow @CarlyHFierce
> Medicaid health plans demand state help to cover pricey new hep C drugs. Article
> Lilly's end of the road on Evista looms with FDA nod for Teva generic. News
Drug Delivery News
> AstraZeneca looks to pen injector approval to turn Bydureon diabetes sales around. Story
> Teva, Alexza launch inhaled schizophrenia, bipolar treatment in the U.S. News
> Neos collects $15.5 from private investors to bring ADHD extended-release option to market. News
> Study: In two-drug, HIV-preventing vaginal ring, only one drug does the job. Article
> New manufacturing technique offers tailored delivery nanoparticles made of iron, silver and silicon. Story
> Tattoo-mediated delivery offers possible treatment for sandfly-borne skin disease. Brief
Diagnostics News
> J. Craig Venter raises $70M for a gene-sequencing and therapeutic startup. News
> Sequenom counts on prenatal test growth to reverse its fortunes. Story
> Qiagen launches its HPV test in India with low-resource areas in mind. Article
> Biodesix's CE mark triggers wider access for its personalized lung cancer treatment Dx. Story
> NEJM study scores Illumina prenatal test high for reducing false positives. Research
> CardioDx confronts tough reimbursement climate by touting cost-effective CAD test. Brief
Pharma Marketing News
> It's trial by fire for Zogenix, as painkiller Zohydro's launch meets public furor. Story
> Sanofi expands Kynamro marketing team to spark up sales. News
> Critics may play whack-a-mole on pharma's doctor-speakers, but the species lives on. Article
> Can Teva persuade payers that pricey long-acting Copaxone beats cheap generics? Article
> Aiming for big growth in top 5 meds, Bayer will stake an extra $600M on marketing, R&D. Story
> With tough Japanese enforcers eyeing its Blopress marketing, Takeda chief admits missteps. Brief